PARK2 gene and familial lung cancer: What is the link?

Future Oncology

Volumn 11, Issue 12, 2015, Pages 1707-1710

  Xiong, Donghai ^a   Wang, Yian ^a   You, Ming ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

exome sequencing; familial lung cancer; genomics; mutations; PARK2

Indexed keywords

PARKIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE;

CANCER CELL; CELL CYCLE; CELL GROWTH; CELL SURVIVAL; FAMILIAL LUNG CANCER; GENE; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; GENETICS; GENOMIC INSTABILITY; HOMEOSTASIS; HUMAN; LOSS OF FUNCTION MUTATION; LUNG CANCER; METABOLISM; MISSENSE MUTATION; MUTATION; ONCOGENE; PARK2 GENE; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; STRESS; TUMOR CELL LINE; XENOPHAGY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; LUNG TUMOR; TUMOR SUPPRESSOR GENE;

GENES, TUMOR SUPPRESSOR; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MUTATION; UBIQUITIN-PROTEIN LIGASES;

EID: 84931479471     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.79     Document Type: Review

References (20)

1. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
2. Gao G, Smith DI. Very large common fragile site genes and their potential role in cancer development. Cell Mol. Life Sci. 71, 4601-4615 (2014).
3. Xiong D, Wang Y, Kupert E et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am. J. Hum. Genet. 96, 301-308 (2015).
4. Gong Y, Zack TI, Morris LG et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat. Genet. 46, 588-594 (2014).
5. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87, 159-170 (1996).
6. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004).
7. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
8. Witkowski L, Carrot-Zhang J, Albrecht S et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 46(5), 438-443 (2014).
9. Bartek J, Hodny Z. PARK2 orchestrates cyclins to avoid cancer. Nat. Genet. 46, 527-528 (2014).
10. Veeriah S, Taylor BS, Meng S et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet. 42, 77-82 (2010).
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
12. Society AC. Cancer Facts & Figures 2011 (2011). www.cancer.org
13. Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008).
14. Wang Y, McKay JD, Rafnar T et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat. Genet. 46, 736-741 (2014).
15. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE, Rothschild H. Increased familial risk for lung cancer. J. Natl Cancer Inst. 76, 217-222 (1986).
16. Liu P, Vikis HG, Wang D et al. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J. Natl Cancer Inst. 100, 1326-1330 (2008).
17. You M, Wang D, Liu P et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin. Cancer Res. 15, 2666-2674 (2009).
18. Cookson MR, Lockhart PJ, McLendon C, O'Farrell C, Schlossmacher M, Farrer MJ. RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 12, 2957-2965 (2003).
19. Sriram SR, Li X, Ko HS et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 14, 2571-2586 (2005).
20. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001).